Combination therapies: The next logical Step for the treatment of synucleinopathies?
Identifieur interne : 000287 ( Main/Exploration ); précédent : 000286; suivant : 000288Combination therapies: The next logical Step for the treatment of synucleinopathies?
Auteurs : Elvira Valera [États-Unis] ; Eliezer Masliah [États-Unis]Source :
- Movement disorders : official journal of the Movement Disorder Society [ 1531-8257 ] ; 2015.
Abstract
Currently there are no disease-modifying alternatives for the treatment of most neurodegenerative disorders. The available therapies for diseases such as Parkinson's disease (PD), PD dementia (PDD), dementia with Lewy bodies (DLB), and multiple system atrophy (MSA), in which the protein alpha-synuclein (α-Syn) accumulates within neurons and glial cells with toxic consequences, are focused on managing the disease symptoms. However, using strategic drug combinations and/or multi-target drugs might increase the treatment efficiency when compared with monotherapies. Synucleinopathies are complex disorders that progress through several stages, and toxic α-Syn aggregates exhibit prion-like behavior spreading from cell to cell. Therefore, it follows that these neurodegenerative disorders might require equally complex therapeutic approaches to obtain significant and long-lasting results. Hypothetically, therapies aimed at reducing α-Syn accumulation and cell-to-cell transfer, such as immunotherapy against α-Syn, could be combined with agents that reduce neuroinflammation with potential synergistic outcomes. Here we review the current evidence supporting this type of approach, suggesting that such rational therapy combinations, together with the use of multi-target drugs, may hold promise as the next logical step for the treatment of synucleinopathies. © 2015 International Parkinson and Movement Disorder Society.
DOI: 10.1002/mds.26428
PubMed: 26388203
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000028
- to stream PubMed, to step Curation: 000028
- to stream PubMed, to step Checkpoint: 000288
- to stream Ncbi, to step Merge: 004490
- to stream Ncbi, to step Curation: 004490
- to stream Ncbi, to step Checkpoint: 004490
- to stream Main, to step Merge: 000287
- to stream Main, to step Curation: 000287
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Combination therapies: The next logical Step for the treatment of synucleinopathies?</title><author><name sortKey="Valera, Elvira" sort="Valera, Elvira" uniqKey="Valera E" first="Elvira" last="Valera">Elvira Valera</name><affiliation wicri:level="2"><nlm:affiliation>Department of Neurosciences, University of California, San Diego, La Jolla, California, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurosciences, University of California, San Diego, La Jolla, California</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Masliah, Eliezer" sort="Masliah, Eliezer" uniqKey="Masliah E" first="Eliezer" last="Masliah">Eliezer Masliah</name><affiliation wicri:level="2"><nlm:affiliation>Department of Neurosciences, University of California, San Diego, La Jolla, California, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurosciences, University of California, San Diego, La Jolla, California</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2015">2015</date><idno type="doi">10.1002/mds.26428</idno><idno type="RBID">pubmed:26388203</idno><idno type="pmid">26388203</idno><idno type="wicri:Area/PubMed/Corpus">000028</idno><idno type="wicri:Area/PubMed/Curation">000028</idno><idno type="wicri:Area/PubMed/Checkpoint">000288</idno><idno type="wicri:Area/Ncbi/Merge">004490</idno><idno type="wicri:Area/Ncbi/Curation">004490</idno><idno type="wicri:Area/Ncbi/Checkpoint">004490</idno><idno type="wicri:Area/Main/Merge">000287</idno><idno type="wicri:Area/Main/Curation">000287</idno><idno type="wicri:Area/Main/Exploration">000287</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Combination therapies: The next logical Step for the treatment of synucleinopathies?</title><author><name sortKey="Valera, Elvira" sort="Valera, Elvira" uniqKey="Valera E" first="Elvira" last="Valera">Elvira Valera</name><affiliation wicri:level="2"><nlm:affiliation>Department of Neurosciences, University of California, San Diego, La Jolla, California, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurosciences, University of California, San Diego, La Jolla, California</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Masliah, Eliezer" sort="Masliah, Eliezer" uniqKey="Masliah E" first="Eliezer" last="Masliah">Eliezer Masliah</name><affiliation wicri:level="2"><nlm:affiliation>Department of Neurosciences, University of California, San Diego, La Jolla, California, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurosciences, University of California, San Diego, La Jolla, California</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author></analytic><series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title><idno type="eISSN">1531-8257</idno><imprint><date when="2015" type="published">2015</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Currently there are no disease-modifying alternatives for the treatment of most neurodegenerative disorders. The available therapies for diseases such as Parkinson's disease (PD), PD dementia (PDD), dementia with Lewy bodies (DLB), and multiple system atrophy (MSA), in which the protein alpha-synuclein (α-Syn) accumulates within neurons and glial cells with toxic consequences, are focused on managing the disease symptoms. However, using strategic drug combinations and/or multi-target drugs might increase the treatment efficiency when compared with monotherapies. Synucleinopathies are complex disorders that progress through several stages, and toxic α-Syn aggregates exhibit prion-like behavior spreading from cell to cell. Therefore, it follows that these neurodegenerative disorders might require equally complex therapeutic approaches to obtain significant and long-lasting results. Hypothetically, therapies aimed at reducing α-Syn accumulation and cell-to-cell transfer, such as immunotherapy against α-Syn, could be combined with agents that reduce neuroinflammation with potential synergistic outcomes. Here we review the current evidence supporting this type of approach, suggesting that such rational therapy combinations, together with the use of multi-target drugs, may hold promise as the next logical step for the treatment of synucleinopathies. © 2015 International Parkinson and Movement Disorder Society.</div></front></TEI><affiliations><list><country><li>États-Unis</li></country><region><li>Californie</li></region></list><tree><country name="États-Unis"><region name="Californie"><name sortKey="Valera, Elvira" sort="Valera, Elvira" uniqKey="Valera E" first="Elvira" last="Valera">Elvira Valera</name></region><name sortKey="Masliah, Eliezer" sort="Masliah, Eliezer" uniqKey="Masliah E" first="Eliezer" last="Masliah">Eliezer Masliah</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000287 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000287 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:26388203
|texte= Combination therapies: The next logical Step for the treatment of synucleinopathies?
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:26388203" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a MovDisordV3
| This area was generated with Dilib version V0.6.23. |  |